

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

H3K27me3-human

RRID:AB_2616029

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9733, RRID:AB_2616029

Antibody Information

URL: http://antibodyregistry.org/AB_2616029

Proper Citation: Cell Signaling Technology Cat# 9733, RRID:AB_2616029

Target Antigen: H3K27me3

Host Organism: rabbit

Clonality: unknown

Comments: ENCODE PROJECT External validation DATA SET is released testing lot 10 for not specified; status is awaiting lab characterization. ENCODE PROJECT External validation DATA SET is released testing lot 1 for not specified; status is not eligible for new data. ENCODE PROJECT External validation DATA SET is released testing lot 1 for any cell type or tissues; status is awaiting lab characterization. Consolidated with AB_1147656, and AB_1147655 on 09/21/16

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: H3K27me3-human

Description: This unknown targets H3K27me3

Target Organism: homo sapiens

Antibody ID: AB_2616029

Vendor: Cell Signaling Technology

Catalog Number: 9733

Alternative Catalog Numbers: ENCAB155VEG

Record Creation Time: 20250819T231405+0000

Record Last Update: 20250820T044236+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 1 is available under ENCODE ID: ENCAB000AQY - ENCODE
<https://www.encodeproject.org/antibodies/ENCAB000AQY>

No alerts have been found for H3K27me3-human.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 365 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Tickman BI, et al. (2026) The response to kidney injury is epigenetically regulated through the activation of bivalent genes. American journal of physiology. Renal physiology, 330(2), F238.

Janssens DH, et al. (2026) Sequential RNA polymerase II activation drives human hematopoiesis. Cell reports, 45(1), 116802.

Vargas C, et al. (2026) The TRIP12's intrinsically disordered region induces chromatin condensates and interferes with nuclear processes. iScience, 29(2), 114592.

Gil J, et al. (2026) Unique territorial and compartmental organization of chromosomes in the holocentric silkworm. The EMBO journal, 45(5), 1573.

Ingersoll S, et al. (2026) Self-clustering of three CBX2 molecules drives PRC2 to promote facultative heterochromatinization of Polycomb target genes. Molecular cell, 86(6), 1015.

Hamam-Marawi G, et al. (2026) CRISPR/Cas9-mediated editing of ERCC6 in iPSCs: A disease model for Cockayne Syndrome type B. Stem cell research, 95, 104044.

Wang L, et al. (2026) The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Developmental cell, 61(6), 1208.

Agius SC, et al. (2026) Accessory subunits of PRC2 mimic H3K27me3 to restrict the spread of Polycomb domains. *Molecular cell*, 86(6), 1032.

Kuser-Abali G, et al. (2026) Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP. *Molecular cell*, 86(13), 2521.

Stokes MS, et al. (2026) NAD⁺ sensing by PARP7 regulates the C/EBP β -dependent transcription program during adipogenesis. *Cell reports*, 45(2), 116929.

Cheng R, et al. (2026) Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21- and OTUD4-mediated EZH2 ubiquitination. *British journal of pharmacology*, 183(11), 2675.

Kandror EK, et al. (2026) Enhancer dynamics and cellular architecture in the human spinal cord. *Neuron*, 114(8), 1399.

Purohit TA, et al. (2026) Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. *Neoplasia* (New York, N.Y.), 73, 101289.

Yamanaka S, et al. (2026) An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation. *Molecular cell*, 86(7), 1397.

Luo Y, et al. (2026) mRNA 3' UTRs chaperone intrinsically disordered regions to control protein activity. *Cell*, 189(15), 4619.

Bready D, et al. (2026) A developmentally regulated long-range enhancer-promoter contact mediates human neural development. *bioRxiv : the preprint server for biology*.

Wang S, et al. (2026) Purinergic signaling promotes gliomagenesis through nuclear calcium transients. *bioRxiv : the preprint server for biology*.

Nocente MC, et al. (2026) Poising and connectivity of emergent human developmental enhancers in the transition from naive to primed pluripotency. *Cell reports*, 45(6), 117402.

Wang Y, et al. (2026) NuMA promotes constitutive heterochromatin compaction by stabilizing linker histone H1 on chromatin. *Cell reports*, 45(2), 116901.